The World Is Entering the Peptide Era

From $36.5B Tirzepatide revenue to a $1T+ market cap at Eli Lilly — peptides are the fastest-growing category in wellness and longevity.

See Why Now Download Our Presentation
What Are Peptides?
Peptides are short chains of amino acids — the natural signaling molecules your body already produces to regulate essential processes like metabolism, tissue repair, weight management, and performance.
Unlike traditional drugs, peptides work by closely mimicking your body's own chemistry, delivering targeted benefits with remarkable precision.
GLP-1 peptide therapies are now the fastest-growing drug class in history — treating obesity, diabetes, cardiovascular disease, and more.
The science is just getting started.

Peptides unlock wellness by closely mimicking the body's natural chemical signals and processes

Weight Loss Fat Loss Joint Regeneration Energy Boost Muscle Growth Faster Recovery Deeper Sleep Anti-Aging Skin Rejuvenation
Peptides unlock wellness
The Peptide Era

GLP-1 Was Just the Beginning

$36.5B

Tirzepatide revenue in 2025

$1T

Eli Lilly market cap built on peptide-driven growth

97%+

of eligible patients are still not using GLP-1 therapy (42% of all Americans are the TAM)

Peptides are now searched more than pickleball on Google Trends
Tirzepatide generated more revenue than Starbucks' entire North American business
$27.5B
2025 Starbucks NA Revenue
75%
74% of total Tirzepatide revenue
The GLP-3 Opportunity

What the Market Doesn't Know Yet

GLP-1 Was the Opening Act. Retatrutide (GLP-3) May Be the Main Event.

What It Is

Retatrutide is a triple hormone receptor agonist (GIP + GLP-1 + glucagon) in Phase 3 trials by Eli Lilly. Early data shows superior weight loss outcomes vs. Tirzepatide, with emerging evidence for metabolic, cardiovascular, and human optimization applications well beyond fat loss.

Why It Matters

Phase 3 clinical data is generating significant institutional attention. The human optimization story — muscle preservation, metabolic health, cognitive function, longevity — expands the TAM dramatically beyond the 42% GLP-1-eligible population. This is the transition from weight drug to longevity drug.

Why Primus Is Ready

Our platform is molecule-agnostic. When Retatrutide clears regulatory hurdles, Primus has the physician network, compounding pharmacy relationships, compliant prescribing infrastructure, and 90K+ patient dataset to commercialize it faster than any new entrant could build from scratch.

Regulatory Momentum

  • RFK Jr. + Trump administration signaling major deregulation in compounded peptides & personalized medicine
  • GLP-1 / Retatrutide / emerging peptide therapies now in Phase 3 with transformative data beyond weight loss
  • Clear path for BPC-157 reactivation and next-gen molecules
  • Primus was built compliant from day one — we don't need to adapt, we're already there
Regulatory Momentum

Exclusive Investor Updates

Join forward-thinking investors and strategic partners for exclusive updates on Primus's growth, regulatory momentum, and next-generation pipeline opportunities — with early access to the full investor presentation and future capital opportunities.

We respect your privacy. Unsubscribe anytime.